# Rigel Pharmaceuticals

Source: https://onco.cc/companies/rigel-pharmaceuticals/  
OnCo record `rigel-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.

## Summary

Rigel Pharmaceuticals, based in South San Francisco and listed as RIGL, commercialises olutasidenib, sold as Rezlidhia, an IDH1 inhibitor for relapsed acute myeloid leukaemia, alongside fostamatinib. Olutasidenib was approved on 1 December 2022 for relapsed or refractory IDH1-mutated AML, and Rigel licensed it from Forma Therapeutics, later part of Novo Nordisk, in 2022. OnCo links it to acute myeloid leukaemia and to the olutasidenib drug record. Whether a second IDH1 inhibitor can take share from the first on durability or tolerability is the open question for a company that did not discover the drug it sells. Olutasidenib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.rigel.com
- Ticker: RIGL

## Sources

- Official website: https://www.rigel.com

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Fostamatinib](https://onco.cc/drugs/fostamatinib/), [Olutasidenib](https://onco.cc/drugs/olutasidenib/), [Pralsetinib](https://onco.cc/drugs/pralsetinib/)
- trials: [Study of Olutasidenib and Temozolomide in HGG](https://onco.cc/trials/nct06161974/), [Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)](https://onco.cc/trials/nct05308264/)

---
JSON: https://onco.cc/api/v1/entities/rigel-pharmaceuticals.json